Showing 2,676 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

Merck, J&J’s New Hepatitis C Treatments Fetch $31,000 in France

Editor's pick
Bloomberg
4 April 2011
New & experimental hepatitis C treatment

Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients at EASL 2011

Editor's pick
Business Wire
4 April 2011
Liver disease

Atazanavir safe and effective for HIV/HCV patients with cirrhosis

News
4 April 2011
New & experimental hepatitis C treatment

Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment

Editor's pick
Eurekalert HIV
2 April 2011
Hepatitis C transmission & prevention

First vaccine for viral hepatitis C could become a reality

Editor's pick
Eurekalert Inf Dis
1 April 2011
New & experimental hepatitis C treatment

Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189

Editor's pick
Pipeline Review
1 April 2011
New & experimental hepatitis C treatment

'Fantastic' data on Novartis' first-in-class hep C antiviral

Editor's pick
Pharma Times
1 April 2011
New & experimental hepatitis C treatment

Well-known statin could be recycled as HCV therapy supplement

Editor's pick
EASL
1 April 2011
Hepatitis C treatment

We’re getting there: towards a comprehensive hepatitis C cure

News
1 April 2011
Hepatitis C treatment

EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection

Editor's pick
EASL
31 March 2011
New & experimental hepatitis C treatment

Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful

Editor's pick
Business Wire
31 March 2011
New & experimental hepatitis C treatment

Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C

Editor's pick
Business Wire
31 March 2011
New & experimental hepatitis C treatment

Telaprevir Improves Viral Cure Rates After Previous Treatment Failure

Editor's pick
Poz magazine news
31 March 2011
Hepatitis & HIV

UCLA study finds cholesterol regulator plays key role in development of liver scarring, cirrhosis

Editor's pick
Eurekalert Medicine & Health
30 March 2011
New & experimental hepatitis C treatment

Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes

Editor's pick
PR Newswire
30 March 2011
Hepatitis C treatment

Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor

Editor's pick
Business Wire
30 March 2011
Exposure to HIV through medical procedures

Could HIV-infected organs save lives?

Editor's pick
Eurekalert HIV
30 March 2011
New & experimental hepatitis C treatment

Achillion ACH-1625 hepatitis drug shows promise in mid-stage trial

Editor's pick
Reuters
30 March 2011
Hepatitis B

Entecavir and Truvada an option for HBV for treatment-experienced HIV/HBV-co-infected patients

News
30 March 2011
Hepatitis B

Accelerated HBV vaccination schedule an option for HIV patients if CD4 cell count is high

News
30 March 2011
Hepatitis C treatment

Copy of Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease

Editor's pick
Kaiser Daily Global Health Policy Report
24 March 2011
Hepatitis C treatment

Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease

Editor's pick
AIDSMeds
24 March 2011
New & experimental hepatitis C treatment

Next Stage for Biotron's Hep C Drug

Editor's pick
Hepatitis Central
23 March 2011
Hepatitis C transmission & prevention

Hepatitis C infection among recent initiates to injecting in England 2000–2008

Editor's pick
Drug and Alcohol Findings
23 March 2011